ILMN · NASDAQ
Illumina, Inc.
$269.75 +0.41 (+0.15%)
Company overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis, along with genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NASDAQ
- Market cap
- $40.7B
- Employees
- 8,970
- Headquarters
- San Diego, CA
- Website
- illumina.com
- CEO
- Jacob Thaysen
- Listed
- July 28, 2000
- P/E
- 48.69
- Dividend yield
- 0.00%
Company financials
- Revenue
- $4.4B
- Gross profit
- $3B
- Operating income
- $942M
- EBITDA
- $1.2B
- Net income
- $853M
- EPS
- $5.54
- Total assets
- $6.6B
- Total debt
- $2.5B
- Gross margin
- 67.66%
- Net margin
- 19.43%
- Earnings yield
- 2.05%
Showing FY 2025
ILMN
1D
NASDAQ
O281.42H283.55L257.31C269.40-13.46 (-4.76%)Vol2.22M